Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP)
Actas Dermo-Sifiliográficas · 2026
DOI: 10.1016/j.ad.2025.104489 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von M Munera-Campos und 31 weiteren Autor:innen. Beteiligte Einrichtung: Departmentd of Dermatología, Hospital Universitari Germans Trias i Pujol, Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Germans T…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Randomized Controlled Trials as Topic, Patient Selection. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Randomized clinical trials (RCTs) supporting advanced treatments for atopic dermatitis (AD) involve highly selected patients, limiting their generalizability. OBJECTIVE: To determine the proportion of adults on advanced systemic therapy for AD in clinical practice who are underrepresented in RCTs and compare the safety and drug survival of these treatments between RCT-eligible and RCT-ineligible patients. MATERIAL AND METHODS: Descriptive and comparative analysis of data from the Spanish Atopic Dermatitis registry BIOBADATOP. Patients were deemed RCT-ineligible if they met, at least, 1 of 8 common exclusion factors: age≥65 years; pregnancy desire pregnancy or lactation; uncontrolled hypertension, cardiovascular disease, or diabetes; chronic kidney disease; cancer diagnosis; liver disease; history of tuberculosis, human immunodeficiency virus or hepatitis B or C infection; and active or acute infection. RESULTS: Of the 366 adults in BIOBADATOP on advanced systemic therapies for AD, 18.3% would be considered ineligible to participate in RCTs. Ineligible patients were older and had more comorbidities than eligible patients. Inclusion of an EASI score
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departmentd of Dermatología, Hospital Universitari Germans Trias i Pujol, Departament de Medicina, Universitat Autonoma de Barcelona (UAB), Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain. El…
- Hospital Universitario de Gran Canaria Doctor Negrín; Las Palmas de Gran Canaria, Spain.
- Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
- Servicio de Dermatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Servicio de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain.
- Servicio de Dermatología, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs, Granada, Spain.
Zitieren
APA
Munera-Campos, M., González Quesada, A., Espasandín Arias, M., Lasheras-Pérez, M. A., de la Cueva Dobao, P., Montero-Vilchez, T., Ruiz-Villaverde, R., Chicharro, P., Gilaberte, Y., Elosua-González, M., Curto Barredo, L., Pereyra-Rodríguez, J. J., Silvestre Salvador, J. F., Batalla, A., Arias-Santiago, S., Navarro Triviño, F. J., Navarro Bielsa, A., Roustan Gullón, G., Bertolín-Colilla, M., …, & Carrascosa Carrillo, J. M. (2026). Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP). Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2025.104489
Vancouver
Munera-Campos M, González Quesada A, Espasandín Arias M, Lasheras-Pérez MA, de la Cueva Dobao P, Montero-Vilchez T, et al. Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP). Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2025.104489
BibTeX
@article{MuneraCampos2026,
author = {Munera-Campos, M and González Quesada, A and Espasandín Arias, M and Lasheras-Pérez, M A and de la Cueva Dobao, P and Montero-Vilchez, T and Ruiz-Villaverde, R and Chicharro, P and Gilaberte, Y and Elosua-González, M and Curto Barredo, L and Pereyra-Rodríguez, J J and Silvestre Salvador, J F and Batalla, A and Arias-Santiago, S and Navarro Triviño, F J and Navarro Bielsa, A and Roustan Gullón, G and Bertolín-Colilla, M and Betlloch-Mas, I and Castaño, I and Couselo-Rodríguez, C and Rodríguez-Serna, M and Sanabria-de la Torre, R and Ruiz Carrascosa, J C and Sánchez, J and Rosell Díaz, Á and Giménez Arnau, A M and Martínez-Fernández, S and García-Doval, I and Descalzo-Gallego, M Á and Carrascosa Carrillo, J M},
title = {Characteristics, Treatment, and Safety Profile of Patients With Atopic Dermatitis According to Eligibility for Randomized Clinical Trials: An Analysis From the Spanish Atopic Dermatitis Registry (BIOBADATOP)},
journal = {Actas Dermo-Sifiliográficas},
year = {2026},
doi = {10.1016/j.ad.2025.104489}
}
EUVIMED